NeuroDerm, an Israeli clinical-stage pharmaceutical company, announced that patients with moderate to severe Parkinson’s disease who received continuous, subcutaneous doses of liquid levodopa/carbidopa (LD/CD) (ND0612L) exhibited improvements in their condition.
The Positive Topline Results of a Phase II, Placebo-Controlled Study s were presented at The Michael J. Fox Foundation’s 2014 Parkinson ’s Disease Therapeutics Conference in New York.
Parkinson’s is possibly one of the two most dreadful diseases to suffer from, along with Alzheimer’s. It not only causes your body to deteriorate, but it also takes away a person’s mental faculties.
It is a progressive neurodegenerative illness characterized by reduced dopamine in the brain, resulting in a debilitating decrease in the patient’s motor and non-motor functions. Its symptoms, such as trembling in the extremities and face, slowness of movement and impaired balance and coordination, worsen over time and gravely impact the patient’s quality of life. As the disease progresses, these symptoms become more severe, resulting in debilitating periods of decreased motor and non-motor functions, also referred to as “off” time. In addition, mainly as a result of excessive/intermittent oral doses of levodopa aimed at treating the “off” time, some patients experience involuntary movements, or dyskinesia.
“The results of these two mid-stage studies show that continuous, subcutaneous dosing with the world’s first-ever liquid formulation of levodopa, the gold standard treatment for Parkinson’s disease, helps overcome the poor pharmacokinetics associated with oral therapy that often have debilitating ramifications for patients, ” said Sheila Oren, M.D., NeuroDerm Vice President of Clinical and Regulatory Affairs, who presented the data of both studies at the meeting.
“These encouraging results reinforce our belief that steady levodopa concentrations translate to clinical benefits. The clinically-significant impact on reduction in ‘off’ time and the positive outcomes from the other exploratory efficacy endpoints, suggest that ND0612L should have a profound impact on patients’ quality of life by greatly improving disease symptoms, while ND0612H may be a very attractive alternative to surgical intervention in advanced patients.”
ND0612H and ND0612L are designed to significantly reduce motor complications in Parkinson’s disease patients through continuous, subcutaneous delivery of LD/CD, maintaining steady, therapeutic levodopa plasma concentrations both day and night. ND0612H is intended to provide an alternative to surgical treatments associated with serious side effects that are currently offered to patients with severe Parkinson’s disease.